MILNACIPRAN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Milnacipran Hydrochloride, and when can generic versions of Milnacipran Hydrochloride launch?
Milnacipran Hydrochloride is a drug marketed by Amneal Pharms and Uspharma Windlas and is included in two NDAs.
The generic ingredient in MILNACIPRAN HYDROCHLORIDE is milnacipran hydrochloride. There are twenty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the milnacipran hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MILNACIPRAN HYDROCHLORIDE?
- What are the global sales for MILNACIPRAN HYDROCHLORIDE?
- What is Average Wholesale Price for MILNACIPRAN HYDROCHLORIDE?
Summary for MILNACIPRAN HYDROCHLORIDE
Recent Clinical Trials for MILNACIPRAN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mansoura University | N/A |
Yousra Hisham Abdel Fattah | N/A |
Allergan | Phase 4 |
Pharmacology for MILNACIPRAN HYDROCHLORIDE
Drug Class | Serotonin and Norepinephrine Reuptake Inhibitor |
Mechanism of Action | Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for MILNACIPRAN HYDROCHLORIDE
Paragraph IV (Patent) Challenges for MILNACIPRAN HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SAVELLA | Tablets | milnacipran hydrochloride | 12.5 mg, 25 mg, 50 mg, and 100 mg | 022256 | 8 | 2013-01-14 |